← Back to Clinical Trials
Recruiting NCT05733442

NCT05733442 Counseling for Harm Reduction and Retention in Medication-assisted Treatment - Cherokee Nation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05733442
Status Recruiting
Phase
Sponsor Washington State University
Condition Opioid Use Disorder
Study Type INTERVENTIONAL
Enrollment 136 participants
Start Date 2023-01-17
Primary Completion 2025-06-30

Trial Parameters

Condition Opioid Use Disorder
Sponsor Washington State University
Study Type INTERVENTIONAL
Phase N/A
Enrollment 136
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2023-01-17
Completion 2025-06-30
Interventions
Treatment as usual (TAU)CHaRRM-CN

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The goal of this randomized clinical trial is to test the efficacy of a program meant to enhance Counseling for Harm Reduction and Retention in MAT in Cherokee Nation (CHaRRM-CN). The main questions it aims to answer are whether CHaRRM-CN: improves retention of patients in MAT, decreases substance-related harm and illicit opioid use, and increases cultural connectedness. After providing written, informed consent, participants will attend a baseline assessement and will then be randomized to either the CHaRRM-CN or treatment as usual group. For 6 months after randomization, participants will be exposed to CHaRRM-CN or treatment as usual. During that time, participants will also attend the 1-month, 3-month and 6-month follow-ups to track their progress through the programs. After the 6 months of either treatment condition, investigators will compare the groups to see if they differ on retention, substance-use outcomes and Native enculturation.

Eligibility Criteria

Inclusion Criteria: 1. At least 18 years of age 2. Must be newly registered (within 4 weeks) in the CNHS MAT Program. (Prior patients can participate as long as their most recent treatment course was at least 6 months prior). 3. Must be willing to provide written informed consent to enroll in this study Exclusion Criteria: 1. Refusal or inability to consent to participation in research. (The latter is assessed using the UCSD Brief Assessment of Capacity to Consent.) 2. Refusal or inability to consent and constituting a risk to the safety and security of other patients or staff

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology